Literature DB >> 15006492

Mitochondria, synaptic plasticity, and schizophrenia.

Dorit Ben-Shachar1, Daphna Laifenfeld.   

Abstract

The conceptualization of schizophrenia as a disorder of connectivity, i.e., of neuronal?synaptic plasticity, suggests abnormal synaptic modeling and neuronal signaling, possibly as a consequence of flawed interactions with the environment, as at least a secondary mechanism underlying the pathophysiology of this disorder. Indeed, deficits in episodic memory and malfunction of hippocampal circuitry, as well as anomalies of axonal sprouting and synapse formation, are all suggestive of diminished neuronal plasticity in schizophrenia. Evidence supports a dysfunction of mitochondria in schizophrenia, including mitochondrial hypoplasia, and a dysfunction of the oxidative phosphorylation system, as well as altered mitochondrial-related gene expression. Mitochondrial dysfunction leads to alterations in ATP production and cytoplasmatic calcium concentrations, as well as reactive oxygen species and nitric oxide production. All of the latter processes have been well established as leading to altered synaptic strength or plasticity. Moreover, mitochondria have been shown to play a role in plasticity of neuronal polarity, and studies in the visual cortex show an association between mitochondria and synaptogenesis. Finally, mitochondrial gene upregulation has been observed following synaptic and neuronal activity. This review proposes that mitochondrial dysfunction in schizophrenia could cause, or arise from, anomalies in processes of plasticity in this disorder.

Entities:  

Mesh:

Year:  2004        PMID: 15006492     DOI: 10.1016/S0074-7742(04)59011-6

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  69 in total

1.  Oxidative stress in schizophrenia: pathogenetic and therapeutic implications.

Authors:  Jeffrey K Yao; Ravinder Reddy
Journal:  Antioxid Redox Signal       Date:  2011-05-04       Impact factor: 8.401

Review 2.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

4.  Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunctionand Cognitive Deficits in a Mouse Model of NMDA Hypofunction.

Authors:  Aarron Phensy; Kathy L Lindquist; Karen A Lindquist; Dania Bairuty; Esha Gauba; Lan Guo; Jing Tian; Heng Du; Sven Kroener
Journal:  J Neurosci       Date:  2020-06-30       Impact factor: 6.167

Review 5.  Brain circuits regulating energy homeostasis.

Authors:  Alfonso Abizaid; Tamas L Horvath
Journal:  Regul Pept       Date:  2008-03-25

Review 6.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

7.  Creatine abnormalities in schizophrenia and bipolar disorder.

Authors:  Dost Ongür; Andrew P Prescot; J Eric Jensen; Bruce M Cohen; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2009-02-23       Impact factor: 3.222

Review 8.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

9.  MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.

Authors:  Olivier C Maes; Howard M Chertkow; Eugenia Wang; Hyman M Schipper
Journal:  Curr Genomics       Date:  2009-05       Impact factor: 2.236

10.  Exon expression in lymphoblastoid cell lines from subjects with schizophrenia before and after glucose deprivation.

Authors:  Maureen V Martin; Brandi Rollins; P Adolfo Sequeira; Andrea Mesén; William Byerley; Richard Stein; Emily A Moon; Huda Akil; Edward G Jones; Stanley J Watson; Jack Barchas; Lynn E DeLisi; Richard M Myers; Alan Schatzberg; William E Bunney; Marquis P Vawter
Journal:  BMC Med Genomics       Date:  2009-09-22       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.